Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973961 | 0.94 | GRIN2B (0.42) | GRM5SMN1; SMN2ARALDH1A1BTK | |
| SCHEMBL4700278 | 0.87 | GRM5 (0.45) | GRM5SMN1; SMN2ARALDH1A1KDM4E | |
| SCHEMBL973549 | 0.77 | SCN8A (0.40) | GRM5ALDH1A1 | |
| SCHEMBL973942 | 0.77 | TRPM8 (0.43) | GRM5ARKMT2A | |
| SCHEMBL8228886 | 0.75 | EPHX1 (0.50) | ALDH1A1GRIN2BGAA | |
| SCHEMBL972008 | 0.73 | VCP (0.43) | GRM5SMN1; SMN2ALDH1A1MEN1TSHR | |
| SCHEMBL971723 | 0.73 | SLC6A7 (0.54) | GRM5ARALDH1A1MEN1TSHR | |
| SCHEMBL4704626 | 0.73 | GAA (0.42) | SMN1; SMN2ARALDH1A1MEN1TSHR | |
| SCHEMBL975221 | 0.72 | SCN8A (0.45) | GRM5ALDH1A1GRIN2B | |
| SCHEMBL3144822 | 0.72 | SLC6A7 (0.58) | GRM5ARALDH1A1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871999-B2 | Substituted thiazoles and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2011-01-18 | — | — | US | claimed |
| EP-1968957-B1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2010-01-20 | — | — | EP | claimed |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-07-09 | — | — | US | claimed |
| WO-2007079960-A9 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2008-10-23 | — | — | WO | claimed |
| US-7871999-B2 | Substituted thiazoles and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1968957-B1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| WO-2007079960-A9 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2008-10-23 | — | — | WO | disclosed |
| EP-1968957-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079960-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, SLC5A2, DPP4 | GRM5 1623/4885SMN1; SMN2 4756/4885AR 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.